Evidence map›Paper›PMID 41306345›Full record

ReviewCambridge prisms. Precision medicine2025

Accelerating eSource scale-up in oncology clinical trials: The i~HD Task Force initiative.

Christophe Maes, Dipak Kalra, Tracy Acito, Nadir Ammour, Paul Basset, Sarah Burge, Peter Castleyn, Ross Caldow, Camille Couvert, Amy Cramer and 21 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cambridge prisms. Precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Christophe MaesFaculty of Medicine and Health Sciences, Department of Public, Ghent University, Ghent, Belgium.
Dipak KalraEuropean Institute for Innovation through Health Data, Ghent, Belgium.
Tracy AcitoRegeneron Pharmaceuticals, Terrytown, NY, USA.
Nadir AmmourSanofi Recherche and Développement, Paris, France.
Paul BassetSanofi Recherche and Développement, Paris, France.
Sarah BurgeCambridge University Hospitals NHS Foundation Trust, Cambridge,UK.
Peter CastleynEuropean Institute for Innovation through Health Data, Ghent, Belgium.
Ross CaldowRegeneron Pharmaceuticals, Terrytown, NY, USA.
Camille CouvertSanofi Recherche and Développement, Paris, France.
Amy CramerJohnson & Johnson, Beerse, Belgium.
Chris HarrisonAstraZeneca One MedImmune Way Gaithersburg, MD, USA.
Joeri HoltzemJohnson & Johnson, Beerse, Belgium.
Pavitra MariappanAstraZeneca One MedImmune Way Gaithersburg, MD, USA.
Paul JacobsRegeneron Pharmaceuticals, Terrytown, NY, USA.
Lars FranssonAstraZeneca R&D Gothenburg, Sweden.
Veronique BerthouSanofi Recherche and Développement, Paris, France.
Laurice JacksonEli Lilly & Company Lilly Corporate Center, Indianapolis, IN, USA.
Nancy WetzelEli Lilly & Company Lilly Corporate Center, Indianapolis, IN, USA.
Christopher ThompsonEli Lilly & Company Lilly Corporate Center, Indianapolis, IN, USA.
Sharon KleinEli Lilly & Company Lilly Corporate Center, Indianapolis, IN, USA.
Robert GreenJohnson & Johnson, Beerse, Belgium.
Fakhry KaoukdjiAstraZeneca R&D Gothenburg, Sweden.
Michael WardEli Lilly & Company Lilly Corporate Center, Indianapolis, IN, USA.
Felix NensaInstitute for Artificial Intelligence in Medicine (IKIM), University Hospital Essen, Essen, Germany.
Joe LengfellnerMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna PatrunoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Dawn SnowSanofi Recherche and Développement, Paris, France.
Isabel VirchowInstitute for Artificial Intelligence in Medicine (IKIM), University Hospital Essen, Essen, Germany.
Angela FritscheMayo Clinic Comprehensive Cancer Center Clinical Trials Office, Rochester, MN, USA.
Pascal CoorevitsFaculty of Medicine and Health Sciences, Department of Public, Ghent University, Ghent, Belgium.
Mats SundgrenEuropean Institute for Innovation through Health Data, Ghent, Belgium.ORCID https://orcid.org/0009-0005-9171-2218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

eSource - particularly EHR-to-EDC - is an emerging paradigm in clinical research that enables automated transfer of electronic health record (EHR) data into electronic data capture (EDC) systems, with the potential to reduce site burden, improve data quality and accelerate oncology clinical trial workflows. However, widespread implementation remains limited due to technical, regulatory and operational barriers. To address these challenges, the European Institute for Innovation through Health Data (i~HD) launched the eSource Scale-Up Task Force in 2024. This multi-stakeholder initiative brings together leading oncology centres and pharmaceutical sponsors to establish a consensus-driven roadmap for eSource adoption. Central to this effort are three foundational resources: readiness criteria for early adopters, a performance indicator framework for monitoring success and an operational playbook to guide implementation. This article provides a structured overview of the Task Force's objectives, collaborative model and outputs, with specific attention to its focus on interoperability, regulatory alignment and real-world validation. While initially developed for oncology, the Task Force's framework is applicable across therapeutic areas characterized by data-intensive workflows.

Indexed as

clinical trial digitizationEHR-to-EDC data integrationeSource implementationoncology clinical trialsresearch workflow optimization

Identifiers

PMID41306345
PMCPMC12644958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.